<DOC>
	<DOCNO>NCT01392703</DOCNO>
	<brief_summary>The purpose study compare blood level dasatinib healthy participant receive tablet formulation healthy participant receive liquid tablet-dispersed formulation drug .</brief_summary>
	<brief_title>Pharmacokinetic Study Comparing Blood Levels Dasatinib Healthy Participants Who Received Tablet Formulation With Those Who Received Liquid Tablet-dispersed Formulations</brief_title>
	<detailed_description />
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Key Healthy participant , define clinically relevant deviation normal medical history , physical examination , electrocardiogram ( ECG ) finding , clinical laboratory test finding . Body mass index 18 32 kg/m^2 , inclusive Age 18 55 year Men woman childbearing potential ( ie , postmenopausal surgically sterile ) All woman must negative serum urine pregnancy test result ( minimum sensitivity 25 IU/L equivalent unit human chorionic gonadotropin ) screening within 24 hour prior dose study drug Women must breastfeed Sexually active fertile men female partner childbearing potential require abide requirement use effective birth control entire study 90 day date last treatment Men must agree donate sperm entire study 90 day day last study treatment Participants must agree make blood donation , include red blood cell , plasma , platelet , whole blood , entire study 8 week day last study treatment Key Any significant acute chronic medical illness Current recent ( within 3 month study drug administration ) disease gastrointestinal ( GI ) tract may impact drug absorption may affect pharmacokinetics study drug GI tract surgery may impact drug absorption Any major surgery , determine investigator , within 4 week dose Period 1 Blood transfusion within 4 week study drug administration Donation &gt; 400 mL blood within 8 week prior study dose donation plasma within 4 week prior study dose Inability tolerate oral medication Inability tolerate orange juice Inability undergo venipuncture and/or tolerate venous access Use tobacco nicotinecontaining product within 6 month prior checkin , positive nicotine test screen and/or checkin Consumption 3 cup coffee caffeinecontaining product day , 5 cup tea day Recent ( within 6 month study drug administration ) drug alcohol abuse Positive blood screen hepatitis C antibody ; hepatitis B surface antigen ; HIV1 , HIV2 , HIV antibody History significant drug allergy asthma Evidence organ dysfunction clinically relevant deviation normal physical examination , ECG finding , vital sign , clinical laboratory test finding . Any following 12lead ECG prior study drug administration , confirm repeat ECG : PR ≥210 m QRS ≥120 m QT ≥500 m QTcF ≥450 m</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>